A case of INR elevation with remdesivir and warfarin in a hospitalized patient with COVID-19

Liyan Yao, William Byas, Matthew Li, Merjona Saliaj


Treatments for COVID-19 infection have varied widely within the past year. Remdesivir is the only direct-acting antiviral approved by the Food and Drug Administration with demonstrated efficacy in the management of patients with COVID-19.[1] Commonly reported adverse effects include hepatotoxicity and gastrointestinal symptoms such as nausea and diarrhea. Less common adverse effects include respiratory toxicity, cardiovascular toxicity and nephrotoxicity.[2] We report a case of international normalized ratio (INR) prolongation in a COVID-19 patient receiving concomitant warfarin and remdesivir therapy.

Full Text:


DOI: https://doi.org/10.5430/crim.v8n1p9


  • There are currently no refbacks.

Case Reports in Internal Medicine

ISSN 2332-7243(Print)  ISSN 2332-7251(Online)

Copyright © Sciedu Press

To make sure that you can receive messages from us, please add the ‘sciedupress.com’ domains to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', please check your 'spam' or 'junk' folder.